Up-Front Payments. Genentech will make the following nonrefundable, non-creditable payment to Magainin of $5 Million in exchange for such form of common equity described in the Stock Purchase Agreement, dated of even date herewith, immediately upon the closing of the Stock Purchase Agreement.
Appears in 2 contracts
Sources: License and Collaboration Agreement (Magainin Pharmaceuticals Inc), License and Collaboration Agreement (Magainin Pharmaceuticals Inc)